Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Raw Materials (2022 - 2025)

Jin Medical International's Raw Materials history spans 4 years, with the latest figure at $2.1 million for Q3 2025.

  • For Q3 2025, Raw Materials rose 1.76% year-over-year to $2.1 million; the TTM value through Sep 2025 reached $2.1 million, up 1.76%, while the annual FY2025 figure was $2.1 million, 1.76% up from the prior year.
  • Raw Materials for Q3 2025 was $2.1 million at Jin Medical International, up from $2.1 million in the prior quarter.
  • Across five years, Raw Materials topped out at $3.3 million in Q3 2022 and bottomed at $2.1 million in Q3 2024.
  • The 4-year median for Raw Materials is $2.4 million (2023), against an average of $2.5 million.
  • The largest annual shift saw Raw Materials dropped 21.31% in 2024 before it rose 1.76% in 2025.
  • A 4-year view of Raw Materials shows it stood at $3.3 million in 2022, then fell by 20.04% to $2.6 million in 2023, then decreased by 21.31% to $2.1 million in 2024, then increased by 1.76% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for ZJYL's Raw Materials are $2.1 million (Q3 2025), $2.1 million (Q3 2024), and $2.6 million (Q3 2023).